Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 May;27(5):295-9.
doi: 10.1002/clc.4960270512.

Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study

Marius Berman  1 , Arie Erman, Tuvia Ben-Gal, Dan Dvir, Georgios P Georghiou, Alon Stamler, Yaffa Vered, Bernardo A Vidne, Dan Aravot
Affiliations
Clinical Trial

Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study

Marius Berman et al. Clin Cardiol. 2004 May.

Abstract

Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.

Hypothesis: The purpose of the present double-blind, placebo-controlled, randomized study was to assess the effect of CoQ10 on patients with end-stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.

Methods: A prospective double-blind design was used. Thirty-two patients with end-stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome--CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6-min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.

Results: Twenty-seven patients completed the study. The study group showed significant improvement in the 6-min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.

Conclusions: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end-stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.

PubMed Disclaimer

Comment in

References

    1. Lehnininger AI: Oxidation–reduction enzymes and electron transport In Biochemistry, 2nd edition, p. 493–497. New York: Worth Publishers, 1975.
    1. Lowe JS, Mortom RA, Vernon J: Unsaponifiable constituents of kidney in various species. Biochem J 1957; 67: 228–234 - PMC - PubMed
    1. Cunningham NF, Morton RA: Unsaponifiable constituents of liver: Ubiquinone and substance SC in various species. Biochem J 1959; 72: 92–99 - PMC - PubMed
    1. Linn BO, Page AC, Wong EI Wong AL, Gale PH, Shunk GH, Folkers K: Isolation and distribution of coenzyme Q10 in animal tissues. Am Chem Soc 1959; 81: 4007–4010
    1. Crane FL, Hatefi Y, Lester RL, Widmer G: Isolation of a quinone from beef heart mitochondria . Biochem Biophys Acta 1957; 25: 220–221 - PubMed

Publication types

MeSH terms